Immunomedics competitorsClear all

Immunomedics's top competitors include Novartis, ImmunoGen, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Bristol-Myers Squibb, Astellas Pharma, AbbVie and ADC Therapeutics.
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background
Immunomedics
Immunomedics
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
Novartis
Novartis
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
ImmunoGen
ImmunoGen
ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.
AstraZeneca
AstraZeneca
AstraZeneca is a global science-led biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines.
Seattle Genetics
Seattle Genetics
Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells.
Daiichi Sankyo
Daiichi Sankyo
Daiichi Sankyo (第一三共株式会社) is a developer of pharmaceutical products.
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb is a company focused that provides biopharmaceutical products.
Astellas Pharma
Astellas Pharma
Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions.
AbbVie
AbbVie
AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
ADC Therapeutics
ADC Therapeutics
ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers.
Founding Date
Founding Date
1982
Founding Date
1996
Founding Date
1981
Founding Date
1999
Founding Date
1998
Founding Date
2005
Founding Date
1887
Founding Date
1923
Founding Date
2012
Founding Date
2010
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Morris Plains, US HQ
Rödermark, DE
Locations
Basel, CH HQ
Tirana, AL
Bir Mourad Raïs, DZ
Duc, AR
Macquarie Park, AU
Wien, AT
Baku, AZ
see more
Locations
Waltham, US HQ
Locations
Cambridge, GB HQ
Alger, DZ
Buenos Aires, AR
Haedo, AR
Macquarie Park, AU
Macquarie Park, AU
North Ryde, AU
see more
Locations
Bothell, US HQ
Mississauga, CA
Hørsholm, DK
Rueil Malmaison, FR
München, DE
Milano, IT
Schiphol, NL
see more
Locations
Tokyo, JP HQ
Wien, AT
Braine L'alleud, BE
Sao Paulo, BR
São Paulo, BR
Beijing, CN
Shanghai, CN
see more
Locations
New York, US HQ
Wien, AT
Braine L'alleud, BE
Bruxelles, BE
São Paulo, BR
Montréal, CA
Shanghai, CN
see more
Locations
Tokyo, JP HQ
Macquarie Park, AU
Wien, AT
Vilvoorde, BE
São Paulo, BR
Markham, CA
Beijing, CN
see more
Locations
Lake Bluff, US HQ
Alger, DZ
Buenos Aires, AR
Mascot, AU
Wien, AT
Wavre, BE
Sarajevo, BA
see more
Locations
Epalinges, CH HQ
Greater London, GB
New Providence, US
San Mateo, US
Employees
Employees
3666% increase
Employees
110,0004% increase
Employees
795% increase
Employees
76,1008% increase
Employees
1,60523% increase
Employees
16,0334% increase
Employees
32,2006% increase
Employees
15,4553% decrease
Employees
50,0006% increase
Employees
1162% increase
Valuation ($)
Valuation ($)
20.3 b
Valuation ($)
N/A
Valuation ($)
917.8 m
Valuation ($)
204.9 b
Valuation ($)
30.5 b
Valuation ($)
41.2 b
Valuation ($)
172.4 b
Valuation ($)
29.8 b
Valuation ($)
253.6 b
Valuation ($)
605.3 m
Twitter followers
Twitter followers
580
Twitter followers
300.6 k
Twitter followers
1.1 k
Twitter followers
300.3 k
Twitter followers
136
Twitter followers
637
Twitter followers
156.2 k
Twitter followers
50.4 k
Twitter followers
75.7 k
Twitter followers
N/A
Number of tweets (last 30 days)
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
21
Number of tweets (last 30 days)
11
Number of tweets (last 30 days)
39
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
53
Number of tweets (last 30 days)
25
Number of tweets (last 30 days)
41
Number of tweets (last 30 days)
N/A
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
21.3
Average likes per tweet (last 30 days)
4
Average likes per tweet (last 30 days)
19
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
8.5
Average likes per tweet (last 30 days)
5.8
Average likes per tweet (last 30 days)
5.4
Average likes per tweet (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
57.14%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
94.87%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
98.11%
Percentage of tweets with engagement (last 30 days)
96%
Percentage of tweets with engagement (last 30 days)
90.24%
Percentage of tweets with engagement (last 30 days)
N/A
Alexa Website Rank
Alexa Website Rank
N/A
Alexa Website Rank
125724
Alexa Website Rank
413660
Alexa Website Rank
9939
Alexa Website Rank
N/A
Alexa Website Rank
372902
Alexa Website Rank
59338
Alexa Website Rank
187498
Alexa Website Rank
89353
Alexa Website Rank
539230
Employee Rating
Employee Rating
2.9
Employee Rating
4.2
Employee Rating
3.4
Employee Rating
4.1
Employee Rating
4
Employee Rating
3.9
Employee Rating
3.9
Employee Rating
4.1
Employee Rating
3.9
Employee Rating
4.3

Financial

Revenue (est.)
Revenue (est.)
$295k (FY, 2019)
Revenue (est.)
$52.9b (FY, 2021)
Revenue (est.)
$132.3m (FY, 2020)
Revenue (est.)
$37.4b (FY, 2021)
Revenue (est.)
$2.2b (FY, 2020)
Revenue (est.)
¥1t (FY, 2021)
Revenue (est.)
$46.4b (FY, 2021)
Revenue (est.)
¥1.3t (FY, 2022)
Revenue (est.)
$56.2b (FY, 2021)
Revenue (est.)
$33.9m (FY, 2021)
Cost of goods
Cost of goods
N/A
Cost of goods
($9.7b) (FY, 2021)
Cost of goods
N/A
Cost of goods
($5.9b) (FY, 2021)
Cost of goods
$217.7m (FY, 2020)
Cost of goods
¥353.3b (FY, 2021)
Cost of goods
$9.9b (FY, 2021)
Cost of goods
(¥173.3b) (FY, 2022)
Cost of goods
$17.4b (FY, 2021)
Cost of goods
($1.3m) (FY, 2021)
Gross profit
Gross profit
$295k (FY, 2019)
Gross profit
$45.1b (FY, 2021)
Gross profit
N/A
Gross profit
$32b (FY, 2021)
Gross profit
$2b (FY, 2020)
Gross profit
¥691.6b (FY, 2021)
Gross profit
$36.4b (FY, 2021)
Gross profit
¥1.2t (FY, 2022)
Gross profit
$38.8b (FY, 2021)
Gross profit
$32.6m (FY, 2021)
Net income
Net income
($357.3m) (FY, 2019)
Net income
$24b (FY, 2021)
Net income
($44.4m) (FY, 2020)
Net income
$115m (FY, 2021)
Net income
$613.7m (FY, 2020)
Net income
¥67b (FY, 2021)
Net income
$7b (FY, 2021)
Net income
¥124.1b (FY, 2022)
Net income
$11.5b (FY, 2021)
Net income
($230m) (FY, 2021)

Operating

Countries
Countries
N/A
Countries
N/A
Countries
N/A
Countries
100 (FY, 2020)
Countries
N/A
Countries
N/A
Countries
N/A
Countries
N/A
Countries
70 (FY, 2020)
Countries
N/A
Manufacturing Facilities
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
13 (Jun, 2022)
Manufacturing Facilities
8 (FY, 2021)
Manufacturing Facilities
N/A
Manufacturing Facilities
24 (FY, 2020)
Manufacturing Facilities
N/A
Patent Applications
Patent Applications
N/A
Patent Applications
N/A
Patent Applications
600 (FY, 2020)
Patent Applications
N/A
Patent Applications
N/A
Patent Applications
367 (Jun, 2022)
Patent Applications
N/A
Patent Applications
N/A
Patent Applications
N/A
Patent Applications
N/A
Patent Applications (US)
Patent Applications (US)
275 (Sep, 2020)
Patent Applications (US)
N/A
Patent Applications (US)
N/A
Patent Applications (US)
N/A
Patent Applications (US)
N/A
Patent Applications (US)
N/A
Patent Applications (US)
N/A
Patent Applications (US)
N/A
Patent Applications (US)
375 (Aug, 2021)
Patent Applications (US)
N/A
Patents (US)
Patents (US)
390 (Sep, 2020)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
729 (Aug, 2021)
Patents (US)
N/A
Patients Included in Clinical Trials
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
33 k (FY, 2017)
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
104 k (FY, 2018)
Patients Included in Clinical Trials
N/A
Phase I Trials Products
Phase I Trials Products
2 (FY, 2019)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
16 (FY, 2018)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products (Immunology)
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
6 (FY, 2021)
Phase I Trials Products (Immunology)
1 (Oct, 2020)
Phase I Trials Products (Immunology)
2 (Mar, 2020)
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Neuroscience)
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
4 (FY, 2021)
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
3 (Mar, 2020)
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Oncology)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
20 (FY, 2021)
Phase I Trials Products (Oncology)
1 (FY, 2020)
Phase I Trials Products (Oncology)
18 (Mar, 2020)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Other)
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
3 (Oct, 2020)
Phase I Trials Products (Other)
1 (Mar, 2020)
Phase I Trials Products (Other)
N/A
Phase II Trials Products
Phase II Trials Products
4 (FY, 2019)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
7 (FY, 2018)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products (Immunology)
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
6 (FY, 2021)
Phase II Trials Products (Immunology)
1 (Oct, 2020)
Phase II Trials Products (Immunology)
6 (Mar, 2020)
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Oncology)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
15 (FY, 2021)
Phase II Trials Products (Oncology)
1 (FY, 2020)
Phase II Trials Products (Oncology)
3 (Mar, 2020)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Other)
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
2 (Oct, 2020)
Phase II Trials Products (Other)
2 (Mar, 2020)
Phase II Trials Products (Other)
N/A
Phase III Trials Products
Phase III Trials Products
4 (FY, 2019)
Phase III Trials Products
54 (FY, 2021)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
7 (FY, 2018)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products (Immunology)
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
3 (FY, 2021)
Phase III Trials Products (Immunology)
1 (Oct, 2020)
Phase III Trials Products (Immunology)
11 (Mar, 2020)
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Oncology)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
27 (FY, 2021)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
7 (FY, 2021)
Phase III Trials Products (Oncology)
4 (Oct, 2020)
Phase III Trials Products (Oncology)
13 (Mar, 2020)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Other)
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
1 (Oct, 2020)
Phase III Trials Products (Other)
1 (Mar, 2020)
Phase III Trials Products (Other)
N/A
Research and Development Centers
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
11 (FY, 2021)
Research and Development Centers
N/A
Research and Development Centers
14 (FY, 2020)
Research and Development Centers
N/A

Funding

Total funding raised
Total funding raised
$ 30m
Total funding raised
$ 6.5m
Total funding raised
$ 56m
Total funding raised
$ 1b
Total funding raised
$ 164m
Total funding raised
N/A
Total funding raised
$ 15.5m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 526m
For sources of this data, please see the company profile

View company profiles

Novartis
HQ
Basel, CH
Employees
110,000↑ 4% increase

Novartis is a company that researches, develops, manufactures, and markets healthcare products.

View company
ImmunoGen
HQ
Waltham, US
Employees
79↑ 5% increase

ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.

View company
AstraZeneca
HQ
Cambridge, GB
Employees
76,100↑ 8% increase

AstraZeneca is a global science-led biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines.

View company
Seattle Genetics
HQ
Bothell, US
Employees
1,605↑ 23% increase

Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells.

View company